---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-038044"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2023-10-24T23:59:59+00:00"
generated_at: "2026-06-09T14:15:05.945354+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Evofem Q3 preliminary net product sales $5.0-5.2M; loss from ops down >80% YoY

## Summary
- Phexxi net product sales expected $5.0-5.2M for Q3 2023; on track for third consecutive year of growth.
- Selling/marketing expenses >75% lower, total operating expenses >65% lower versus Q3 2022.
- Loss from operations reduced >80% YoY; expects lowest quarterly operating loss to date.
- Fourth amendment to convertible notes: may repurchase $25M notes for as little as $14M; initial $1M paid.
- Generic competitor amended ANDA; will not seek FDA approval until Phexxi patents expire in 2033.

## SEC filing metadata
- accession: 0001493152-23-038044
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2023-10-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315223038044/0001493152-23-038044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315223038044/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-038044
- JSON: https://secwatch.observer/filing/0001493152-23-038044.json
- Plain text: https://secwatch.observer/filing/0001493152-23-038044.txt

## Key facts
- Earnings Releases
  Evofem Biosciences, Inc. reported the third quarter of 2023 results: revenue $5.0 to $5.2 million.
  - Period: the third quarter of 2023
  - Revenue: $5.0 to $5.2 million
  - Result: preliminary results
  source text: gel, Phexxi ® (lactic acid, citric acid and potassium bitartrate) and the positive impact of ongoing cost containment initiatives. ● Phexxi net product sales expected to be $5.0 to $5.2 million for the third quarter of 2023. ● Evofem remains on track to deliver its third consecutive year of net product sales growth. ● Selling and marketing expenses were
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000149315223038044/0001493152-23-038044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.